Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Hanze Zhang"'
Autor:
Ashit Trivedi, Winnie Sohn, Priyanka Kulkarni, Pegah Jafarinasabian, Hanze Zhang, Marintan Spring, Stephen Flach, Siddique Abbasi, Jan Wahlstrom, Edward Lee, Sandeep Dutta
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 6, Pp 2510-2520 (2021)
Abstract Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patien
Externí odkaz:
https://doaj.org/article/86aa2e97af2349d6999630760b8de569
Publikováno v:
Sensors, Vol 23, Iss 4, p 2243 (2023)
With the rise of latency-sensitive and computationally intensive applications in mobile edge computing (MEC) environments, the computation offloading strategy has been widely studied to meet the low-latency demands of these applications. However, the
Externí odkaz:
https://doaj.org/article/945b1ca10f66425badc87446c4e54651
Autor:
Jing Zhou, Li He, Ping Liu, Hui Duan, Hanze Zhang, Weili Li, Shipeng Gong, Guidong Su, Chunlin Chen
Publikováno v:
PLoS ONE, Vol 11, Iss 11, p e0165610 (2016)
To study the therapeutic effects of uterine artery embolization (UAE) on adenomyosis and to investigate the association between uterine blood supply and artery embolization treatment outcomes.Using digital subtraction angiography (DSA) imaging data,
Externí odkaz:
https://doaj.org/article/5525313d782f4ba69dda2b991d3fb3a6
Autor:
Barbara Langland-Orban PhD, John T. Large PhD, Alan M. Sear PhD, Hanze Zhang MSPH, Nanhua Zhang PhD
Publikováno v:
Inquiry: The Journal of Health Care Organization, Provision, and Financing, Vol 52 (2015)
Medicare Advantage was implemented in 2004 and the Recovery Audit Contractor (RAC) program was implemented in Florida during 2005. Both increase surveillance of medical necessity and deny payments for improper admissions. The purpose of the present s
Externí odkaz:
https://doaj.org/article/dfd8a1afd1bb40339f197b3f0210c5db
Autor:
Winnie Sohn, Jan Wahlstrom, Marintan Spring, Hanze Zhang, Siddique Abbasi, Stephen Flach, Sandeep Dutta, Priyanka Kulkarni, Ashit Trivedi, Edward Lee, Pegah Jafarinasabian
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 6, Pp 2510-2520 (2021)
Clinical and Translational Science, Vol 14, Iss 6, Pp 2510-2520 (2021)
Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with h
Publikováno v:
Academy of Management Proceedings. 2022
Autor:
Sandeep Dutta, Bianca Terminello, Pegah Jafarinasabian, Winnie Sohn, Siddique Abbasi, Hanze Zhang, Edward Lee, Ashit Trivedi, Stephen Flach
Publikováno v:
Clinical Pharmacology in Drug Development. 11:129-133
Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure (HF) with reduced ejection fraction. OM is administered as a 25-, 37.5-, or 50-mg modified-release formulation in patients with HF. Proton p
Autor:
Stephen Flach, Ashit Trivedi, Siddique Abbasi, Sandeep Dutta, Fady I. Malik, Hanze Zhang, Pegah Jafarinasabian, Edward Lee
Publikováno v:
Clinical Pharmacology in Drug Development. 11:185-193
Omecamtiv mecarbil (OM) is a cardiac myosin activator under development for the treatment of heart failure. The effect of CYP3A4 and CYP2D6 inhibition on OM pharmacokinetics and the potential for OM to induce CYP3A4 was assessed in 2 studies. Study 1
Autor:
Edward Lee, Mia Mackowski, Hanze Zhang, Sandeep Dutta, Ashit Trivedi, Stephen Flach, Ajay Bhatia, Pegah Jafarinasabian, Bianca Terminello
Publikováno v:
Clinical Drug Investigation. 41:639-645
Omecamtiv mecarbil (OM) is a cardiac myosin activator under clinical development for the treatment of heart failure. Two modified-release (MR) novel OM minitablet formulations were developed to support the planned investigation of chronic heart failu
Autor:
Hanze Zhang, Pegah Jafarinasabian, Shauna Hutton, Siddique Abbasi, Mia Mackowski, Rajneet K. Oberoi, Stephen Flach, Edward Lee, Sandeep Dutta, Ashit Trivedi
Publikováno v:
Clinical Pharmacology in Drug Development. 10:1442-1451
Omecamtiv mecarbil (OM) is a novel selective cardiac myosin activator under investigation for the treatment of heart failure with reduced ejection fraction. OM is primarily eliminated via metabolism mediated by multiple cytochrome P450 enzymes. This